A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method

BACKGROUND: A key challenge in phase I trials is maintaining rapid escalation in order to avoid exposing too many patients to sub-therapeutic doses, while preserving safety by limiting the frequency of toxic events. Traditional rule-based designs require temporarily stopping recruitment whilst waiti...

Descripción completa

Detalles Bibliográficos
Autores principales: North, Bernard, Kocher, Hemant Mahendrakumar, Sasieni, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6595589/
https://www.ncbi.nlm.nih.gov/pubmed/31242873
http://dx.doi.org/10.1186/s12885-019-5801-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6595589/
https://www.ncbi.nlm.nih.gov/pubmed/31242873
http://dx.doi.org/10.1186/s12885-019-5801-3

Ejemplares similares